Meningiomas, Nerve Sheath Tumors, and Pituitary Tumors: Diagnosis and Treatment

Hematology/Oncology Clinics of North America

Volumn 26, Issue 4, 2012, Pages 855-879

  Roser, Florian ^a   Honegger, Jürgen ^a   Schuhmann, Martin U ^a   Tatagiba, Marcos S ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Meningioma; Nerve sheath tumor; Pituitary tumor

Indexed keywords

BEVACIZUMAB; CALCIUM ANTAGONIST; GROWTH HORMONE; HYDROXYUREA; IMATINIB; SOMATOSTATIN; TEMOZOLOMIDE;

ACROMEGALY; BRAIN SCINTIANGIOGRAPHY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CUSHING DISEASE; ENDOCRINE FUNCTION TEST; ENDOSCOPY; GAMMA KNIFE RADIOSURGERY; GIGANTISM; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS FUNCTION; HYPOPHYSIS TUMOR; MENINGIOMA; NERVE SHEATH TUMOR; NEUROIMAGING; NEURONAVIGATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTINOMA; RADIATION DOSE; RADIOSURGERY; REVIEW; STEREOTACTIC RADIOSURGERY; SURGICAL TECHNIQUE; TRANSSPHENOIDAL SURGERY; VISUAL SYSTEM EXAMINATION;

BRAIN; DIAGNOSTIC IMAGING; HUMANS; MENINGIOMA; NERVE SHEATH NEOPLASMS; PITUITARY NEOPLASMS;

EID: 84863859849     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.04.005     Document Type: Review

References (139)

1. Eisenhardt L., Cushing H. Diagnosis of intracranial tumors by supravital technique. Am J Pathol 1930, 6(5):541-552.
2. Claus E.B., Bondy M.L., Schildkraut J.M., et al. Epidemiology of intracranial meningioma. Neurosurgery 2005, 57(6):1088-1095. [discussion: 1088-95].
3. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):97-109.
4. DeAngelis L.M. Brain tumors. N Engl J Med 2001, 344(2):114-123.
5. Jaaskelainen J., Haltia M., Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986, 25(3):233-242.
6. Matsuno A., Fujimaki T., Sasaki T., et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol (Berl) 1996, 91(5):504-510.
7. Albrecht S., Goodman J.C., Rajagopolan S., et al. Malignant meningioma in Gorlin's syndrome: cytogenetic and p53 gene analysis. Case report. J Neurosurg 1994, 81(3):466-471.
8. Lindboe C.F., Helseth E., Myhr G. Lhermitte-Duclos disease and giant meningioma as manifestations of Cowden's disease. Clin Neuropathol 1995, 14(6):327-330.
9. Baheti A.D., Mahore A.S., Zade B.P., et al. Meningioma and cavernous angioma following childhood radiotherapy. J Cancer Res Ther 2010, 6(3):333-335.
10. Sadetzki S., Flint-Richter P., Ben Tal T., et al. Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg 2002, 97(5):1078-1082.
11. Bondy M., Ligon B.L. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 1996, 29(3):197-205.
12. Schuz J., Bohler E., Berg G., et al. Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany). Am J Epidemiol 2006, 163(6):512-520.
13. Roser F., Nakamura M., Ritz R., et al. Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Cancer 2005, 104(3):598-601.
14. Fredman P., Dumanski J., Davidsson P., et al. Expression of the ganglioside GD3 in human meningiomas is associated with monosomy of chromosome 22. J Neurochem 1990, 55(6):1838-1840.
15. Gusella J.F., Ramesh V., MacCollin M., et al. Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta 1999, 1423(2):M29-M36.
16. Rempel S.A., Schwechheimer K., Davis R.L., et al. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 1993, 53(Suppl 10):2386-2392.
17. Ketter R., Henn W., Niedermayer I., et al. Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg 2001, 95(4):601-607.
18. Simon M., von Deimling A., Larson J.J., et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 1995, 55(20):4696-4701.
19. Weber R.G., Bostrom J., Wolter M., et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997, 94(26):14719-14724.
20. Talback M., Stenbeck M., Rosen M. Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data. Eur J Cancer 2004, 40(9):1361-1372.
21. Nakamura M., Roser F., Michel J., et al. The natural history of incidental meningiomas. Neurosurgery 2003, 53(1):62-70.
22. Roser F., Nakamura M., Bellinzona M., et al. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 2004, 57:1033-1037.
23. Goyal L.K., Suh J.H., Mohan D.S., et al. Local control and overall survival in atypical meningioma: a retrospective study. Int J Radiat Oncol Biol Phys 2000, 46(1):57-61.
24. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957, 20:22-39.
25. Chozick B.S., Reinert S.E., Greenblatt S.H. Incidence of seizures after surgery for supratentorial meningiomas: a modern analysis. J Neurosurg 1996, 84(3):382-386.
26. Goldman C.K., Bharara S., Palmer C.A., et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 1997, 40(6):1269-1277.
27. Bitzer M., Opitz H., Popp J., et al. Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor. Acta Neurochir (Wien) 1998, 140(4):333-340.
28. Bitzer M., Wockel L., Morgalla M., et al. Peritumoural brain oedema in intracranial meningiomas: influence of tumour size, location and histology. Acta Neurochir (Wien) 1997, 139(12):1136-1142.
29. de Vries J., Wakhloo A.K. Cerebral oedema associated with WHO-I, WHO-II, and WHO-III-meningiomas: correlation of clinical, computed tomographic, operative and histological findings. Acta Neurochir (Wien) 1993, 125(1-4):34-40.
30. Roser F., Nakamura M., Jacobs C., et al. Sphenoid wing meningiomas with osseous involvement. Surg Neurol 2005, 64(1):37-43. [discussion: 43].
31. Tokgoz N., Oner Y.A., Kaymaz M., et al. Primary intraosseous meningioma: CT and MRI appearance. AJNR Am J Neuroradiol 2005, 26(8):2053-2056.
32. Bendszus M., Rao G., Burger R., et al. Is there a benefit of preoperative meningioma embolization?. Neurosurgery 2000, 47(6):1306-1311.
33. Gruber A., Killer M., Mazal P., et al. Preoperative embolization of intracranial meningiomas: a 17-years single center experience. Minim Invasive Neurosurg 2000, 43(1):18-29.
34. Kaji T., Hama Y., Iwasaki Y., et al. Preoperative embolization of meningiomas with pial supply: successful treatment of two cases. Surg Neurol 1999, 52(3):270-273.
35. Thorwarth D., Henke G., Muller A.C., et al. Simultaneous (68)Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. Int J Radiat Oncol Biol Phys 2011, 81(1):277-283.
36. Solero C.L., Fornari M., Giombini S., et al. Spinal meningiomas: review of 174 operated cases. Neurosurgery 1989, 25(2):153-160.
37. Nakamura M., Roser F., Bundschuh O., et al. Intraventricular meningiomas: a review of 16 cases with reference to the literature. Surg Neurol 2003, 59(6):491-503.
38. Roser F., Nakamura M., Martini-Thomas R., et al. The role of surgery in meningiomas involving the optic nerve sheath. Clin Neurol Neurosurg 2006, 108(5):470-476.
39. Roser F., Nakamura M., Bellinzona M., et al. Proliferation potential of spinal meningiomas. Eur Spine J 2006, 15(2):211-215.
40. Omay S.B., Barnett G.H. Surgical navigation for meningioma surgery. J Neurooncol 2010, 99(3):357-364.
41. Hefti M. Comment concerning: intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas, Acta Neurochir DOl:10.1007/s00701-010-0708-4, Intratumoral heterogeneity and fluorescence intensity in meningioma after 5-ALA pretreatment. Acta Neurochir (Wien) 2011, 153(4):959-960.
42. Chen T.C., Rabb C., Apuzzo M.L. Complex technical methodologies and their applications in the surgery of intracranial meningiomas. Neurosurg Clin N Am 1994, 5(2):261-281.
43. Wallace E.W. The dural tail sign. Radiology 2004, 233(1):56-57.
44. Brell M., Villa S., Teixidor P., et al. Fractionated stereotactic radiotherapy in the treatment of exclusive cavernous sinus meningioma: functional outcome, local control, and tolerance. Surg Neurol 2006, 65(1):28-33. [discussion: 33-4].
45. Dufour H., Muracciole X., Metellus P., et al. Long-term tumor control and functional outcome in patients with cavernous sinus meningiomas treated by radiotherapy with or without previous surgery: is there an alternative to aggressive tumor removal?. Neurosurgery 2001, 48(2):285-294.
46. Nakamura M., Roser F., Dormiani M., et al. Facial and cochlear nerve function after surgery of cerebellopontine angle meningiomas. Neurosurgery 2005, 57(1):77-90. [discussion: 77-90].
47. Nakamura M., Roser F., Dormiani M., et al. Intraoperative auditory brainstem responses in patients with cerebellopontine angle meningiomas involving the inner auditory canal: analysis of the predictive value of the responses. J Neurosurg 2005, 102(4):637-642.
48. Cavanaugh D.A., Jawahar A., Lee J.A., et al. Intraspinal meningioma in a 101-year old: should age determine the aggressiveness of intervention?. Surg Neurol 2008, 69(2):130-134.
49. Caroli E., Acqui M., Roperto R., et al. Spinal en plaque meningiomas: a contemporary experience. Neurosurgery 2004, 55(6):1275-1279.
50. Roser F., Ebner F.H., Ritz R., et al. Management of skull based meningiomas in the elderly patient. J Clin Neurosci 2007, 14(3):224-228.
51. Cornu P., Chatellier G., Dagreou F., et al. Intracranial meningiomas in elderly patients. Postoperative morbidity and mortality. Factors predictive of outcome. Acta Neurochir (Wien) 1990, 102(3-4):98-102.
52. Bateman B.T., Pile-Spellman J., Gutin P.H., et al. Meningioma resection in the elderly: nationwide inpatient sample, 1998-2002. Neurosurgery 2005, 57(5):866-872. [discussion: 866-72].
53. Moffat D.A., Quaranta N., Baguley D.M., et al. Management strategies in neurofibromatosis type 2. Eur Arch Otorhinolaryngol 2003, 260(1):12-18.
54. Baser M.E., Dg R.E., Gutmann D.H. Neurofibromatosis 2. Curr Opin Neurol 2003, 16(1):27-33.
55. Milker-Zabel S., Zabel A., Schulz-Ertner D., et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005, 61(3):809-816.
56. Chuang C.C., Chang C.N., Tsang N.M., et al. Linear accelerator-based radiosurgery in the management of skull base meningiomas. J Neurooncol 2004, 66(1-2):241-249.
57. Iwai Y., Yamanaka K., Ishiguro T. Gamma knife radiosurgery for the treatment of cavernous sinus meningiomas. Neurosurgery 2003, 52(3):517-524.
58. Kondziolka D., Lunsford L.D., Coffey R.J., et al. Gamma knife radiosurgery of meningiomas. Stereotact Funct Neurosurg 1991, 57(1-2):11-21.
59. Lunsford L.D. Contemporary management of meningiomas: radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal?. J Neurosurg 1994, 80(2):187-190. [editorial].
60. Ojemann S.G., Sneed P.K., Larson D.A., et al. Radiosurgery for malignant meningioma: results in 22 patients. J Neurosurg 2000, 93(Suppl 3):62-67.
61. Crocker D., Murtagh F.R., Phuphanich S. Multiple malignant meningiomas following systemic chemotherapy for Hodgkin's lymphoma: a three-dimensional magnetic resonance imaging analysis. J Neuroimaging 1995, 5(1):51-53. [letter].
62. Newton H.B., Slivka M.A., Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 2001, 49(2):165-170.
63. Schrell U.M., Rittig M.G., Anders M., et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 1997, 86(5):840-844. [see comments].
64. Wen P.Y., Yung W.K., Lamborn K.R., et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 2009, 11(6):853-860.
65. Chamberlain M.C., Glantz M.J., Fadul C.E. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007, 69(10):969-973.
66. Chamberlain M.C., Tsao-Wei D.D., Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004, 62(7):1210-1212.
67. Ragel B.T., Gillespie D.L., Kushnir V., et al. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro. Neurosurgery 2006, 59(5):1109-1120. [discussion: 1120-1].
68. Puchner M.J., Hans V.H., Harati A., et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 2010, 21(12):2445-2446.
69. Kantar M., Cetingul N., Kansoy S., et al. Radiotherapy-induced secondary cranial neoplasms in children. Childs Nerv Syst 2004, 20(1):46-49.
70. Mikulec A.A., Kinsella L.J. Subacute brainstem necrosis: a complication of stereotactic radiotherapy for skull base meningioma. Otol Neurotol 2011, 32(7):e50-e51.
71. Norden A.D., Drappatz J., Wen P.Y. Targeted drug therapy for meningiomas. Neurosurg Focus 2007, 23(4):E12.
72. Ezzat S., Asa S.L., Couldwell W.T., et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004, 101(3):613-619.
73. Daly A.F., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91(12):4769-4775.
74. DeLellis R.A., Lloyd R.V., Heitz P.U., et al. Tumours of endocrine organs. World Health Organization classification of tumours 2004, IARC, Lyon (France).
75. Honegger J., Beschorner R., Ernemann U. Perisellar tumours including cysts, hamartomas, and vascular tumours. Oxford textbook of endocrinology and diabetes 2011, 246-259. Oxford University Press, Oxford (NY). J.A. Wass, P.M. Stewart (Eds.).
76. Wass J.A., Trainer P.J., Korbonits M. Acromegaly. Oxford textbook of endocrinology and diabetes 2011, 197-209. Oxford University Press, Oxford (NY). J.A. Wass, P.M. Stewart (Eds.).
77. Yanovski J.A., Cutler G.B. Glucocorticoid action and the clinical features of Cushing's syndrome. Endocrinol Metab Clin North Am 1994, 23(3):487-509.
78. Arnaldi G., Angeli A., Atkinson A.B., et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88(12):5593-5602.
79. Knosp E., Steiner E., Kitz K., et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993, 33(4):610-617. [discussion: 617-8].
80. Ikeda H., Yoshimoto T. Visual disturbances in patients with pituitary adenoma. Acta Neurol Scand 1995, 92(2):157-160.
81. Honegger J., Ernemann U., Psaras T., et al. Objective criteria for successful transsphenoidal removal of suprasellar nonfunctioning pituitary adenomas. A prospective study. Acta Neurochir (Wien) 2007, 149(1):21-29. [discussion: 29].
82. Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 1969, 16:185-217.
83. Griffith H.B., Veerapen R. A direct transnasal approach to the sphenoid sinus. Technical note. J Neurosurg 1987, 66(1):140-142.
84. Jho H.D., Carrau R.L. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 1997, 87(1):44-51.
85. Weiss M.H. Transnasal transsphenoidal approach. Surgery of the third ventricle 1987, 476-494. Williams & Wilkins, Baltimore (MD). M.L. Apuzzo (Ed.).
86. Mason R.B., Nieman L.K., Doppman J.L., et al. Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. J Neurosurg 1997, 87(3):343-351.
87. Zhao B., Wei Y.K., Li G.L., et al. Extended transsphenoidal approach for pituitary adenomas invading the anterior cranial base, cavernous sinus, and clivus: a single-center experience with 126 consecutive cases. J Neurosurg 2010, 112(1):108-117.
88. Nimsky C., von Keller B., Ganslandt O., et al. Intraoperative high-field magnetic resonance imaging in transsphenoidal surgery of hormonally inactive pituitary macroadenomas. Neurosurgery 2006, 59(1):105-114. [discussion: 105-14].
89. Ciric I., Ragin A., Baumgartner C., et al. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997, 40(2):225-236. [discussion: 236-7].
90. Fatemi N., Dusick J.R., Mattozo C., et al. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery 2008, 63(4):709-718. [discussion: 718-9].
91. O'Sullivan E.P., Woods C., Glynn N., et al. The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 2009, 71(5):709-714.
92. Amar A.P., Couldwell W.T., Chen J.C., et al. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 2002, 97(2):307-314.
93. Nomikos P., Buchfelder M., Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005, 152(3):379-387.
94. Hammer G.D., Tyrrell J.B., Lamborn K.R., et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 2004, 89(12):6348-6357.
95. Buchfelder M., Kreutzer J. Transcranial surgery for pituitary adenomas. Pituitary 2008, 11(4):375-384.
96. Webster J., Piscitelli G., Polli A., et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994, 331(14):904-909.
97. Kars M., Pereira A.M., Smit J.W., et al. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 2009, 20(4):387-393.
98. Valassi E., Klibanski A., Biller B.M. Clinical review: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010, 95(3):1025-1033.
99. Dekkers O.M., Lagro J., Burman P., et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95(1):43-51.
100. Freda P.U., Katznelson L., van der Lely A.J., et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90(8):4465-4473.
101. Brue T. ACROSTUDY: status update on 469 patients. Horm Res 2009, 71(Suppl 1):34-38.
102. Biller B.M., Grossman A.B., Stewart P.M., et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008, 93(7):2454-2462.
103. Boscaro M., Ludlam W.H., Atkinson B., et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009, 94(1):115-122.
104. Raverot G., Sturm N., de Fraipont F., et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010, 95(10):4592-4599.
105. Brada M., Rajan B., Traish D., et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993, 38(6):571-578.
106. Estrada J., Boronat M., Mielgo M., et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997, 336(3):172-177.
107. Jenkins P.J., Bates P., Carson M.N., et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006, 91(4):1239-1245.
108. Landolt A.M., Haller D., Lomax N., et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998, 88(6):1002-1008.
109. Sheehan J.P., Niranjan A., Sheehan J.M., et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005, 102(4):678-691.
110. Jagannathan J., Sheehan J.P., Pouratian N., et al. Gamma Knife surgery for Cushing's disease. J Neurosurg 2007, 106(6):980-987.
111. Pollock B.E., Brown P.D., Nippoldt T.B., et al. Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery 2008, 62(6):1271-1276. [discussion: 1276-8].
112. Antonescu C.R., Woodruff J.M. Primary tumors of cranial, spinal and peripheral nerve. Russell and Rubinstein's pathology of tumors of the nervous system 2006, 787-836. Oxford University Press, London, Chapter 56. R.E. McLendon, M.K. Rosenblum, D.D. Bigner (Eds.).
113. Samii M., Migliori M.M., Tatagiba M., et al. Surgical treatment of trigeminal schwannomas. J Neurosurg 1995, 82(5):711-718.
114. Vogel H. Nervous system 2009, Cambridge University Press, New York.
115. Pollack I.F. Brain tumors in children. N Engl J Med 1994, 331(22):1500-1507.
116. Propp J.M., McCarthy B.J., Davis F.G., et al. Descriptive epidemiology of vestibular schwannomas. Neuro Oncol 2006, 8(1):1-11.
117. Tos M., Charabi S., Thomsen J. Incidence of vestibular schwannomas. Laryngoscope 1999, 109(5):736-740.
118. Matthies C., Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery 1997, 40(1):1-9. [discussion: 9-10].
119. Evans D.G., Moran A., King A., et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005, 26(1):93-97.
120. Evans D.G., Lye R., Neary W., et al. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J Neurol Neurosurg Psychiatry 1999, 66(6):764-767.
121. Evans D.G., Huson S.M., Donnai D., et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992, 84(304):603-618.
122. Samii M., Matthies C., Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997, 40(4):696-705. [discussion: 705-6].
123. Duvoisin B., Fernandes J., Doyon D., et al. Magnetic resonance findings in 92 acoustic neuromas. Eur J Radiol 1991, 13(2):96-102.
124. Smouha E.E., Yoo M., Mohr K., et al. Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm. Laryngoscope 2005, 115(3):450-454.
125. Samii M., Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): the facial nerve-preservation and restitution of function. Neurosurgery 1997, 40(4):684-694. [discussion: 694-5].
126. Samii M., Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): hearing function in 1000 tumor resections. Neurosurgery 1997, 40(2):248-260. [discussion: 260-2].
127. Matthies C., Samii M. Management of vestibular schwannomas (acoustic neuromas): the value of neurophysiology for evaluation and prediction of auditory function in 420 cases. Neurosurgery 1997, 40(5):919-929. [discussion: 929-30].
128. Anderson D.E., Leonetti J., Wind J.J., et al. Resection of large vestibular schwannomas: facial nerve preservation in the context of surgical approach and patient-assessed outcome. J Neurosurg 2005, 102(4):643-649.
129. Darrouzet V., Martel J., Enee V., et al. Vestibular schwannoma surgery outcomes: our multidisciplinary experience in 400 cases over 17 years. Laryngoscope 2004, 114(4):681-688.
130. Samii M., Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them. Neurosurgery 1997, 40(1):11-21. [discussion: 21-3].
131. Cerullo L., Grutsch J., Osterdock R. Recurrence of vestibular (acoustic) schwannomas in surgical patients where preservation of facial and cochlear nerve is the priority. Br J Neurosurg 1998, 12(6):547-552.
132. Ohta S., Yokoyama T., Nishizawa S., et al. Regrowth of the residual tumour after acoustic neurinoma surgery. Br J Neurosurg 1998, 12(5):419-422.
133. Hasegawa T., Fujitani S., Katsumata S., et al. Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years. Neurosurgery 2005, 57(2):257-265. [discussion: 257-65].
134. Lunsford L.D., Niranjan A., Flickinger J.C., et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg 2005, 102(Suppl):195-199.
135. Paek S.H., Chung H.T., Jeong S.S., et al. Hearing preservation after gamma knife stereotactic radiosurgery of vestibular schwannoma. Cancer 2005, 104(3):580-590.
136. Evans D.G., Birch J.M., Ramsden R.T., et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006, 43(4):289-294.
137. Mathieu D., Kondziolka D., Flickinger J.C., et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 2007, 60(3):460-468. [discussion: 468-70].
138. Plotkin S.R., Stemmer-Rachamimov A.O., Barker F.G., et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009, 361(4):358-367.
139. Mautner V.F., Nguyen R., Knecht R., et al. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 2010, 21(11):2294-2295.